NPI: 1013995521 · WAUPACA, WI 54981 · Critical Access Hospital · NPI assigned 01/04/2006
Authorized official FLETT, WILLIAM controls 20+ related entities in our dataset. Read more
| Authorized Official | FLETT, WILLIAM (CFO) |
| NPI Enumeration Date | 01/04/2006 |
Other providers sharing the same authorized official: FLETT, WILLIAM
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 31,601 | $836K |
| 2019 | 34,668 | $1.22M |
| 2020 | 38,736 | $1.47M |
| 2021 | 50,675 | $1.61M |
| 2022 | 50,939 | $1.87M |
| 2023 | 50,930 | $1.97M |
| 2024 | 41,213 | $1.87M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 12,702 | 10,251 | $2.12M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7,126 | 6,156 | $1.32M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 8,027 | 6,251 | $1.23M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4,231 | 2,845 | $854K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1,403 | 1,141 | $561K |
| 70450 | Computed tomography, head or brain; without contrast material | 2,398 | 2,125 | $530K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1,991 | 1,790 | $507K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2,685 | 2,361 | $403K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1,578 | 743 | $353K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2,296 | 1,793 | $316K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 730 | 488 | $234K |
| 80048 | Basic metabolic panel (calcium, ionized) | 24,347 | 18,531 | $190K |
| 84443 | Thyroid stimulating hormone (TSH) | 6,992 | 6,287 | $150K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 21,441 | 16,615 | $125K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 815 | 568 | $115K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 915 | 748 | $112K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4,114 | 1,736 | $105K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2,376 | 2,154 | $102K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 356 | 329 | $100K |
| 71046 | Radiologic examination, chest; 2 views | 3,453 | 3,125 | $92K |
| 87631 | 833 | 747 | $61K | |
| 80076 | 11,507 | 9,440 | $61K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 147 | 131 | $58K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 2,350 | 1,159 | $56K |
| 80061 | Lipid panel | 4,983 | 4,624 | $55K |
| 72125 | Computed tomography, cervical spine; without contrast material | 725 | 662 | $50K |
| G0378 | Hospital observation service, per hour | 1,186 | 662 | $48K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2,601 | 1,203 | $48K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2,577 | 1,648 | $46K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 206 | 174 | $43K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 195 | 180 | $41K |
| 83036 | Hemoglobin; glycosylated (A1C) | 4,381 | 4,056 | $39K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1,040 | 845 | $38K |
| 96367 | 248 | 177 | $34K | |
| 84484 | 5,818 | 3,816 | $32K | |
| 80306 | 1,983 | 1,709 | $26K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1,215 | 1,090 | $26K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1,435 | 1,244 | $23K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 3,551 | 3,131 | $21K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 7,173 | 5,790 | $20K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 494 | 455 | $20K |
| 81001 | 8,398 | 7,135 | $19K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 299 | 275 | $18K |
| 85610 | 5,440 | 3,737 | $18K | |
| 83735 | 4,856 | 3,994 | $17K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 549 | 512 | $17K |
| 83690 | 3,863 | 3,340 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,374 | 633 | $16K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 542 | 481 | $16K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 240 | 202 | $16K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 449 | 402 | $15K |
| 83880 | 1,368 | 1,159 | $15K | |
| 81025 | 2,077 | 1,829 | $15K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 466 | 419 | $14K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 66 | 40 | $13K |
| 73564 | 457 | 418 | $13K | |
| 74018 | 291 | 265 | $13K | |
| 84439 | 1,564 | 1,395 | $12K | |
| 97162 | 398 | 373 | $12K | |
| 83605 | 2,659 | 2,069 | $11K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 32 | 27 | $10K |
| 85380 | 1,498 | 1,335 | $9K | |
| 36415 | Collection of venous blood by venipuncture | 23,495 | 18,439 | $8K |
| 87040 | 2,555 | 1,227 | $8K | |
| 82077 | 813 | 688 | $7K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 352 | 300 | $7K |
| 73630 | 319 | 280 | $7K | |
| 80053 | Comprehensive metabolic panel | 766 | 643 | $6K |
| 82728 | 613 | 571 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 129 | 106 | $6K |
| 73610 | 274 | 242 | $6K | |
| 87186 | 1,297 | 1,173 | $6K | |
| 85730 | 2,072 | 1,846 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 340 | 308 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2,642 | 1,999 | $5K |
| 85027 | 1,275 | 1,082 | $5K | |
| 87070 | 540 | 485 | $5K | |
| 86140 | 1,288 | 1,037 | $4K | |
| 71045 | Radiologic examination, chest; single view | 3,630 | 3,169 | $4K |
| 86803 | 392 | 338 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 26 | 24 | $4K |
| 87088 | 898 | 819 | $4K | |
| 82607 | 388 | 331 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5,111 | 4,333 | $4K |
| 84481 | 266 | 229 | $3K | |
| 72100 | 101 | 95 | $3K | |
| 82948 | 1,098 | 528 | $3K | |
| 84703 | 350 | 316 | $3K | |
| 85651 | 792 | 654 | $3K | |
| 93017 | 16 | 13 | $3K | |
| 82570 | 767 | 680 | $3K | |
| 82947 | 1,032 | 704 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 5,004 | 3,869 | $3K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | 59 | 53 | $2K |
| 73030 | 98 | 81 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 13 | 13 | $2K |
| 87807 | 119 | 111 | $2K | |
| 86618 | 63 | 60 | $2K | |
| 83550 | 359 | 331 | $2K | |
| 83540 | 437 | 403 | $2K | |
| 87634 | 31 | 29 | $2K | |
| 82043 | 381 | 346 | $2K | |
| 81003 | 861 | 772 | $2K | |
| 87340 | 187 | 151 | $2K | |
| 85652 | 673 | 572 | $1K | |
| 93971 | 13 | 12 | $1K | |
| 80143 | 118 | 106 | $1K | |
| 80179 | 117 | 105 | $1K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1,568 | 1,258 | $1K |
| 85379 | 206 | 181 | $1K | |
| 96376 | 930 | 716 | $1K | |
| 86850 | 257 | 218 | $1K | |
| 94729 | 27 | 25 | $919.87 | |
| 82962 | 616 | 260 | $876.52 | |
| 73130 | 55 | 50 | $716.33 | |
| 86900 | 317 | 274 | $648.80 | |
| 90715 | 27 | 24 | $624.22 | |
| 97163 | 30 | 26 | $615.97 | |
| 86901 | 317 | 274 | $615.80 | |
| 86780 | 79 | 65 | $601.19 | |
| 82150 | 110 | 102 | $521.39 | |
| 36592 | 137 | 79 | $504.14 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13 | 12 | $478.80 |
| 82565 | 118 | 112 | $474.31 | |
| 73110 | 17 | 15 | $424.63 | |
| 85018 | 256 | 220 | $413.38 | |
| 82550 | 82 | 78 | $359.29 | |
| 85014 | 128 | 108 | $296.42 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,614 | 3,207 | $270.27 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 43 | 39 | $257.74 |
| 86703 | 15 | 14 | $245.18 | |
| 86666 | 15 | 15 | $243.91 | |
| 82805 | 15 | 12 | $241.85 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 61 | 50 | $158.07 |
| 86706 | 16 | 12 | $145.63 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 3,497 | 2,789 | $136.40 |
| J2704 | Injection, propofol, 10 mg | 1,147 | 959 | $121.53 |
| 86753 | 15 | 15 | $114.63 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2,785 | 2,316 | $94.02 |
| 84460 | 31 | 28 | $91.42 | |
| 87081 | 32 | 25 | $87.75 | |
| 87210 | 13 | 12 | $61.86 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 59 | 53 | $55.64 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,267 | 940 | $49.95 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 73 | 66 | $47.82 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 959 | 835 | $45.48 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 1,317 | 1,088 | $32.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 865 | 556 | $22.83 |
| J7050 | Infusion, normal saline solution, 250 cc | 5,224 | 2,662 | $20.51 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 868 | 716 | $8.95 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 822 | 580 | $5.15 |
| A9270 | Non-covered item or service | 624 | 467 | $3.87 |
| J1170 | Injection, hydromorphone, up to 4 mg | 299 | 233 | $3.72 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 13 | 12 | $0.49 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 15 | 12 | $0.38 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 1,221 | 1,012 | $0.04 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 4,346 | 3,452 | $0.03 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 43 | 41 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 47 | 40 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 70 | 58 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 48 | 39 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 31 | 13 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 201 | 167 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 14 | 12 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 29 | 12 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 26 | 23 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 12 | 12 | $0.00 |